Percheron Therapeutics to Conduct Clinical Trial with Vanderbilt Health
Key points
- Percheron collaborates with Vanderbilt Health for HMBD-002 clinical trial in AML/MDS
- Trial aims to start recruitment in 4Q CY2026
- Dr. Somedeb Ball leads the study as Principal Investigator
- Percheron provides financial grant and study drug support
- Trial may provide insights for future clinical development
Full summary
Percheron Therapeutics Limited, an international biotechnology company, has entered into a clinical research agreement with Vanderbilt Health to conduct a multi-centre clinical trial of its drug HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). The trial, led by Dr. Somedeb Ball, will investigate HMBD-002 in combination with standard-of-care treatments for high-risk AML/MDS patients. The study aims to commence recruitment in the fourth quarter of calendar year 2026. HMBD-002, a monoclonal antibody targeting the VISTA immune checkpoint, has shown safety and potential efficacy in previous phase I trials. Vanderbilt Health, a leading healthcare institution in the southeastern United States, will lead the trial design and execution, with Percheron providing financial and technical support.
Guidance
No specific financial guidance provided in the announcement.
Outlook
The trial aims to provide significant insights for future clinical development of HMBD-002 in AML/MDS.
Summary generated by a large language model. Please interpret with care.